No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib

References

• Mock J, Kunk PR, Palkimas S, et al. Risk of major bleeding with ibrutinib. Clin Lymphoma Myeloma Leuk. 2018;18(11):755–761.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
   PubMed Web of Science ®Google Scholar
• Forum UC. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–1572.
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49–56.
   PubMed Web of Science ®Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–1692.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (>/=80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156(2):196–204.
   PubMed Web of Science ®Google Scholar
• Goede V, Cramer P, Busch R, on behalf of the German CLL Study Group, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095–1100.
   PubMed Web of Science ®Google Scholar
• Satram-Hoang S, Reyes C, Hoang KQ, et al. The unmet need in chronic lymphoctytic leukemia: impact of comorbidity burden on treatment patterns and outcomes in elderly patients. JCT. 2013;04(08):1321–1329.
   Google Scholar
• Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80(7):1273–1283.
   PubMed Web of Science ®Google Scholar
• Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165–177.
   PubMed Web of Science ®Google Scholar
• IMS LifeLink. IMS oncology prescription and medical claims database (IMS Health Incorporated, University of Arkansas for Medical Sciences, all rights reserved).
   Google Scholar
• Jones JA, Hillmen P, Coutre S, et al. Pattern of use of anticoagulation and/or antiplatelet agents in patients with chronic lymphocytic leukemia (CLL) treated with single-agent ibrutinib therapy [abstract]. Blood. 2014;124(21):1990–1990.
   Web of Science ®Google Scholar
• Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017;178(2):286–291.
   PubMed Web of Science ®Google Scholar
• Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96(5):752–761.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014;12(6):916–946. Available from: http://williams.medicine.wisc.edu/nhl.pdf
   Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591–594.
   PubMed Web of Science ®Google Scholar
• Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther. 2011;29(1):29–36.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078–2088.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas version 1.2020. [cited 2020 Jun 20]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma version 4.2020. [cited 2020 Jun 20]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Barrientos JC, Meyer N, Song X, et al. Characterization of atrial fibrillation and bleeding risk factors in patients with chronic lymphocytic leukemia (CLL): a population-based retrospective cohort study of administrative medical claims data in the United States (US). Blood. 2015;126(23):3301–3301.
   Web of Science ®Google Scholar
• Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019; 184(4):558–569.
   PubMed Web of Science ®Google Scholar
• Barrientos JC, O’Brien S, Brown JR, et al. Improvement in parameters of hematologic and immunologic function and patient well-being in the Phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(12):803–813 e7.
   PubMed Web of Science ®Google Scholar